Order results by:
| Issue | Title | |
| Vol 11, No 5 (2015) | Practical aspects of apixaban use in clinical practice: continuing the theme | Abstract similar documents |
| S. N. Bel'diev | ||
| "... to avoid apixaban combination with strong CYP3A4 and P-gp inhibitors in patients with a creatinine ..." | ||
| Vol 11, No 2 (2015) | PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST | Abstract similar documents |
| D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii | ||
| "... Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base ..." | ||
| Vol 16, No 5 (2020) | Pharmacokinetics and Pharmacogenetics of Apixaban | Abstract similar documents |
| A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova | ||
| "... . The hypothesis about CYP и SULT1A enzymes influence on apixaban metabolism was examined. To date, numerous SNVs ..." | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... apixaban together with a CYP3A4/P-gp inhibitor were 3.5 times more likely to have hemorrhagic complications ..." | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... that are inhibitors or inducers of the CYP3A4 enzyme or P-glycoprotein enzymes, are determined by most of the drug ..." | ||
| Vol 13, No 1 (2017) | CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova | ||
| "... Aim. To compare cost-effectiveness of the use of direct factor Xa inhibitors rivaroxaban ..." | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| "... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..." | ||
| Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
| Z. M. Safiullina, S. V. Shalaev | ||
| "... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..." | ||
| Vol 14, No 3 (2018) | APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova | ||
| "... as a drug of choice from the P2Y12 inhibitor group, the use of low doses of acetylsalicylic acid (ASA ..." | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... and methods. 117 patients receiving DOAC (direct thrombin inhibitors – dabigatran, and Xa factor inhibitors ..." | ||
| Vol 20, No 1 (2024) | Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis | Abstract similar documents |
| l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev | ||
| "... Aim. The aim of our study was to investigate the influence of polymorphic markers of CYP3A4*22 CYP ..." | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| "... for assessing the blood concentration of factor Xa inhibitors, in particular, a reagent for assessing the level ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... антикоагулянты, в частности, ривароксабан (ингибитор Xa фактора), широко используются при различных показаниях ..." | ||
| Vol 12, No 3 (2016) | THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE | Abstract PDF (Eng) similar documents |
| A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko | ||
| "... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| Vol 10, No 3 (2014) | EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION | Abstract similar documents |
| "... European Medicines Agency approved apixaban use in cardioversion. ..." | ||
| Vol 11, No 6 (2015) | Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events | Abstract similar documents |
| O. V. Shatalova | ||
| "... Aim. Pharmacoeconomic analysis of apixaban use compared to conventional therapy in patients ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| Vol 14, No 2 (2018) | NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING | Abstract similar documents |
| Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov | ||
| "... . In comparison of different DOACs against each other apixaban demonstrated lower bleeding risk while patients ..." | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| Vol 14, No 5 (2018) | Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case | Abstract similar documents |
| M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov | ||
| "... with P2Y12 inhibitor was clinically manifested by repeated thrombotic events and was confirmed ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apixaban ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| "... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... 1045642 polymorphisms. ABCB1 gene rs4148738 polymorphism was associated with higher apixaban peak ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..." | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... : rivaroxaban - 180/384 (46,9%) patients, dabigatran etexilate - 110/384 (28,6%) patients, apixaban - 94/384 (24 ..." | ||
| Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Rudakova, V. A. Parfenov | ||
| "... anticoagulants such as apixaban, rivaroxaban and dabigatran. Administration of vitamin K antagonists (VKA ..." | ||
| Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
| "... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... , rivaroxaban – in 41.3% (n=178), apixaban – in 20.2% (n=87) of patients. Results. The incidence of new cases ..." | ||
| Vol 16, No 2 (2020) | Off-Label Medicines Use: Complex Problem of Modern Clinical Practice | Abstract similar documents |
| S. R. Gilyarevskiy | ||
| Vol 14, No 3 (2018) | THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE | Abstract similar documents |
| I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient ..." | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| Vol 15, No 4 (2019) | Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen | Abstract similar documents |
| A. I. Kochetkov, O. D. Ostroumova | ||
| "... profile and multimorbidity. In these terms, apixaban stands high among the DOAC class, and its high ..." | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| Vol 6, No 1 (2010) | SOME ASPECTS OF THE LISINOPRIL USAGE IN ARTERIAL HYPERTENSION TREATMENT | Abstract similar documents |
| N. A. Jaiani | ||
| "... Рассматриваются обоснования и преимущества применения ингибитора АПФ лизиноприла в практической ..." | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| Vol 16, No 3 (2020) | Clinical and Pathophysiological Aspects of the Effect of Anticoagulants on Bone Tissue | Abstract similar documents |
| O. D. Ostroumova, I. V. Goloborodova | ||
| Vol 7, No 1 (2011) | NEW ANTIPLATELET DRUGS (PART 1) | Abstract similar documents |
| A. B. Sumarokov | ||
| "... antiplatelet drugs are on their way to clinical application — prasugrel, ticagrelor, elinogrel, inhibitors ..." | ||
| Vol 4, No 2 (2008) | ACE INHIBITORS ARE RATIONAL PHARMACOTHERAPY OF ENDOTHELIAL DYSFUNCTION | Abstract similar documents |
| M. P. Metrova, A. B. Salmina, A. I. Inzhutova, O. S. Bahmeteva | ||
| "... Aim. To study effects of ACE inhibitor perindopril on markers of endothelial dysfunction ..." | ||
| Vol 10, No 5 (2014) | CHOICE OF LISINOPRIL FOR TREATMENT OF HYPERTENSION IN PATIENTS WITH CONCOMITANT DISEASES | Abstract similar documents |
| N. A. Dzhaiani | ||
| "... Rationale and benefits of the use of the ACE inhibitor lisinopril in the clinical practice ..." | ||
| Vol 5, No 1 (2009) | ACE INHIBITORS IN ARTERIAL HYPERTENSION TREATMENT: FOCUS ON LISINOPRIL | Abstract similar documents |
| V. I. Podzolkov, K. K. Osadchy | ||
| "... inhibitor lisinopril is surveyed. Data about lisinopril effects on different endpoints, organoprotective ..." | ||
| Vol 7, No 5 (2011) | NEW ANTIPLATELET DRUGS. PART 2 | Abstract similar documents |
| A. B. Sumarokov | ||
| "... are on their way to clinical application — prasugrel, ticagrelor , elinogrel, thromboxane receptor inhibitors ..." | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| Vol 15, No 4 (2019) | According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention | Abstract similar documents |
| Company Pfizer | ||
| Vol 17, No 6 (2021) | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 | Abstract similar documents |
| I. S. Yavelov | ||
| Vol 19, No 1 (2023) | Analysis of The Use of PCSK9 Inhibitors in Clinical Practice | Abstract similar documents |
| S. Yu. Volkova, L. A. Boyarskaya, P. Yu. Toropygin, I. A. Morozov, E. A. Boyarskaya | ||
| "... Aim. The analysis of the experience of using PCSK9 inhibitors (alirocumab) in patients with very ..." | ||
| Vol 19, No 6 (2023) | Acute kidney injury as a risk factor for atrial fibrillation after coronary artery bypass grafting — effects of sodium-glucose cotransporter-2 inhibitors | Abstract similar documents |
| L. V. Kremneva, L. A. Arutyunyan, L. I. Gapon, S. N. Suplotov, S. V. Shalaev | ||
| "... cotransporter 2 (SGLT-2) inhibitors. Material and methods. We examined 92 patients with stable angina who ..." | ||
| Vol 12, No 5 (2016) | Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention | Abstract similar documents |
| E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva | ||
| "... and laboratory biomarkers were assessed before stenting, as well as CYP2C19 genotyping after patient’s discharge ..." | ||
| Vol 5, No 3 (2009) | ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN MANAGEMENT OF PATIENTS WITH CHRONIC HEART FAILURE | Abstract similar documents |
| S. N. Tereshchenko, N. A. Dzhaiani | ||
| "... The role of ACE inhibitors in modern pharmacotherapy of patients with chronic heart failure (CHF ..." | ||
| Vol 10, No 6 (2014) | СONCOMITANT ADMINISTRATION OF CLOPIDOGREL AND PROTON PUMP INHIBITORS: ARE THERE ANY OPEN QUESTIONS LEFT TODAY? | Abstract similar documents |
| S. Yu. Martsevich, A. Yu. Suvorov | ||
| "... Concomitant administration of clopidogrel and proton pump inhibitors (PPI), the possible influence ..." | ||
| Vol 8, No 4 (2012) | EFFECT OF CARDIOVASCULAR DRUGS ON BONE HEALTH AND THE POSSIBILITY OF THEIR USE FOR THE PREVENTION OF OSTEOPOROSIS | Abstract similar documents |
| I. A. Skripnikova, K. E. Sobchenko, O, V. Kosmatova, D. V. Nebieridze | ||
| "... and, first of all beta-blockers, ACE inhibitors, diuretics, and statins on bone are presented. Mode of action ..." | ||
| Vol 4, No 3 (2008) | COMPARATIVE EFFICACY OF ACE INHIBITORS (RAMIPRIL VS ENALAPRIL) IN TREATMENT OF CHRONIC HEART FAILURE IN WOMEN | Abstract similar documents |
| S. N. Tereshchenko, I. V. Zhirov, E. V. Malichenko, E. E. Kazantseva | ||
| Vol 4, No 3 (2008) | ANGIOTENSIN II AND MYOCARDIAL INFARCTION | Abstract similar documents |
| O. P. Shevchenko, А. О. Shevchenko | ||
| "... ) inhibitors reduce mortality and improve prognosis of patients with acute MI. In patients with ischemic heart ..." | ||
| Vol 5, No 2 (2009) | CARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR RAMIPRIL | Abstract similar documents |
| D. A. Napalkov, E. N. Golovenko | ||
| "... There is grate interest to ACE inhibitors which have cardioprotective and neproprotective effects ..." | ||
| Vol 3, No 1 (2007) | THE CAPABILITIES OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CLINICAL PRACTICE: FOCUS ON VASOPROTECTION | Abstract similar documents |
| D. B. Nebieridze, A. S. Safaryan | ||
| "... enzyme (ACE) inhibitors in clinical practice were represented. The traditional usage of ACE eminhibitors/em ..." | ||
| Vol 8, No 2 (2012) | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS | Abstract similar documents |
| A. A. Lomonosova, N. A. Mazur, E. A. Zolozova, E. V. Sayutina, V. V. Chigineva, N. V. Shestakova | ||
| Vol 20, No 2 (2024) | Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements | Abstract similar documents |
| L. D. Khidirova, A. E. Latsvieva, A. V. Vederin | ||
| "... The immune checkpoint eminhibitors/em (ICTs) emergence has opened up new perspectives in cancer ..." | ||
| Vol 6, No 5 (2010) | PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE | Abstract similar documents |
| M. N. Mamedov, G. G. Sharvadze, E. A. Poddubsky, A. K. Ausheva | ||
| "... . The phosphodiesterase-5 (PDE5) eminhibitors/em increase the relaxing effect of nitric oxide and increase cyclic GMP levels ..." | ||
| Vol 1, No 1 (2005) | ACE INHIBITORS IN PATIENTS WITH ISCHEMIC HEART DISEASE WITHOUT HEART FAILURE: CLASS EFFECTS AND EFFICACY OF ITS REPRESENTATIVES | Abstract similar documents |
| Y. A. Karpov | ||
| "... of the role of ACE eminhibitors/em in treatment of patients with stable form of ischemic heart disease without ..." | ||
| Vol 14, No 1 (2018) | COMORBID PATIENT IN GASTROENTEROLOGY: INDIVIDUAL APPROACH | Abstract similar documents |
| I. G. Bakulin, S. A. Sayganov, M. I. Skalinskaya, E. V. Skazyayeva, I. V. Lapinskii | ||
| "... eminhibitors/em, depending on clinical dynamics. The rationale for the replacement of proton pump eminhibitors/em ..." | ||
| Vol 3, No 3 (2007) | ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN ACUTE MYOCARDIAL INFARCTION: WHEN TO START THERAPY AND WHICH DRUG TO USE? | Abstract similar documents |
| S. Y. Martsevich, S. N. Tolpygina | ||
| "... Data of studies devoted to application of angiotensin converting enzyme (ACE) eminhibitors/em in acute ..." | ||
| Vol 6, No 4 (2010) | ACE INHIBITOR POSSIBILITIES IN CLINICAL PRACTICE: WHAT WE KNOW ABOUT THEM? | Abstract similar documents |
| D. V. Nebieridze, A. S. Safarian | ||
| "... New possibilities of ACE eminhibitors/em application on the base of international trails review ..." | ||
| Vol 16, No 4 (2020) | Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues | Abstract similar documents |
| M. V. Zhuravleva, A. B. Prokofiev, E. V. Shikh, S. Yu. Serebrova, G. I. Gorodetskaya, E. Yu. Demchenkova | ||
| "... considers the place of proprotein convertase subtilisin/kexin type 9 (PCSK9) eminhibitors/em in the prevention ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... in this process. Low doses of direct oral eminhibitors/em of thrombin are able to potentiate antithrombotic effect ..." | ||
| Vol 1, No 1 (2005) | EXPERT CONSENSUS DOCUMENT ON ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE | Abstract similar documents |
| Jose Lopez-Sendon, Karl Swedberg, John McMurray, Juan Tamargo, Aldo P. Maggioni, Henry Dargie, Michal Tendera, Finn Waagstein, Jan Kjekshus, Philippe Lechat, Christian Torp-Pedersen | ||
| "... Expert consensus document on angiotensin converting enzyme eminhibitors/em in cardiovascular disease. ..." | ||
| Vol 17, No 6 (2021) | PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center | Abstract similar documents |
| A. V. Blokhina, A. I. Ershova, A. S. Limonova, O. V. Kopylova, A. N. Meshkov, O. M. Drapkina | ||
| "... Aim. To characterize patients receiving PCSK9 eminhibitors/em, and assess the efficiency ..." | ||
| Vol 5, No 4 (2009) | TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS | Abstract similar documents |
| L. N. Malay, A. N. Miroshnichenko, B. V. Sharykin, V. V. Konurovsky | ||
| "... Angiotensin converting enzyme (ACE) eminhibitors/em and angiotensin II receptor blockers (ARB) slow ..." | ||
| Vol 6, No 1 (2010) | COMBINED ANTIHYPERTENSIVE THERAPY: ACE INHIBITOR PLUS CALCIUM CHANNEL BLOCKER. NEW ADVANTAGES OF THE KNOWN COMBINATION | Abstract similar documents |
| S. A. Boitsov, R. M. Linchak | ||
| "... attention is paid to usage of ACE eminhibitor/em and calcium antagonist combination. ..." | ||
| Vol 13, No 2 (2017) | SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. B. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, D. A. Dimitrova | ||
| Vol 6, No 5 (2010) | THE USE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AFTER MYOCARDIAL INFARCTION. WHAT DO EVIDENCE-BASED MEDICINE DATA SPEAK FOR? | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... The main trails proven angiotensin converting enzyme (ACE) eminhibitor/em effects on the life prognosis ..." | ||
| Vol 9, No 4 (2013) | ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... The results of the main large controlled trials that had proven effect of ACE eminhibitors/em (ACEi ..." | ||
| Vol 16, No 2 (2020) | Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... The recent discussion about the dangers of using angiotensin-converting-enzyme (ACE) eminhibitors/em ..." | ||
| Vol 3, No 2 (2007) | RESULTS OF OUTPATIENT PROGRAM ON EFFECTIVE THERAPY OF REFRACTORY ARTERIAL HYPERTENSION | Abstract similar documents |
| M. M. Batyushin, I. V. Derevyankina, M. Z. Gasanov, O. V. Akopova, K. I. Babiyan, Y. N. Boychenko, N. V. Vasilchenko, T. A. Gabysyan, S. Ch. Gayboryan, I. S. Golovatenko, N. M. Demkova, D. O. Dmitriev, E. V. Kirtava, O. L. Kotyankova, G. V. Ludanova, S. A. Lyashenko, A. E. Malichina, O. I. Poroshenko, A. V. Svechnikova, I. Y. Sidorov, E. V. Solyannikova, I. D. Tascheyan, E. A. Heygetyan, S. E. Evruyan | ||
| "... converting enzyme (ACE) eminhibitor/em, thiazid diuretic (indapamide) and dihydropyridine calcium antagonist ..." | ||
| Vol 3, No 5 (2007) | EFFECT OF SPIRAPRIL ON THE LENGTH OF INTERICTAL INTERVAL IN PAROXYSMAL ATRIAL FIBRILLATION | Abstract similar documents |
| L. N. Chikhireva, V. I. Malahov, E. S. Bykova, S. F. Sokolov | ||
| "... Aim. To evaluate effects of angiotensin converting enzyme eminhibitor/em spirapril on efficacy ..." | ||
| Vol 6, No 1 (2010) | ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES | Abstract similar documents |
| E. M. Khurs, A. V. Poddubnaya | ||
| "... Aim. To evaluate the cardioprotective effects of ACE eminhibitor/em, ramipril and angiotensin II ..." | ||
| Vol 9, No 2 (2013) | A META-ANALYSIS REPORTING EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTSWITHOUT HEART FAILURE | Abstract similar documents |
| G. Savarese, P. Costanzo, J.G.F. Cleland, E. Vassallo, D. Ruggiero, G. Rosano, P. Perrone-Filardi | ||
| "... . Rosano, P. Perrone-Filardi «A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme emInhibitors/em ..." | ||
| Vol 11, No 5 (2015) | Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism | Abstract similar documents |
| A. V. Rudakova | ||
| "... Aim. To assess the cost-effectiveness of emapixaban/em in the treatment and secondary prevention ..." | ||
| Vol 8, No 6 (2012) | SARTANS AND ANGIOTENSIN CONVERTING ENZYME INHIBITORS: A DUEL BETWEEN TWO LEADERS OF PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES | Abstract similar documents |
| K. A. Gyamdzhyan, M. L. Maksimov | ||
| "... , angiotensin converting enzyme eminhibitors/em and sartans, are compared. Data from evidence base of the both drug ..." | ||
| Vol 5, No 6 (2009) | ORGANOPROTECTIVE EFFECTS OF THE FIXED COMBINATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITOR LISINOPRIL AND DIURETIC HYDROCHLOROTHIAZIDE | Abstract similar documents |
| E. A. Ryabikhin, M. E. Mozheiko | ||
| Vol 9, No 2 (2013) | FIXED COMBINATION OF THE CALCIUM CHANNEL BLOCKER LERCANIDIPINE AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR ENALAPRIL: POSSIBILITY OF USAGE | Abstract similar documents |
| O. D. Ostroumova, I. I. Kopchenov | ||
| "... converting enzyme (ACE) eminhibitor/em and dihydropyridine calcium antagonist are considered. Data on the efficacy ..." | ||
| Vol 9, No 2 (2013) | ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: ISN'T IT TIME TO DRAW A LINE UNDER DISCUSSION ABOUT SUPERIORITY | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... -Converting Enzyme emInhibitors/em and Angiotensin Receptor Blockers in Patients Without Heart Failure ..." | ||
| Vol 3, No 5 (2007) | CUMULATIVE CARDIO-VASCULAR RISK IN HYPERTENSIVE PATIENTS: EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS | Abstract similar documents |
| L. I. Katelnitskaya, L. A. Haisheva, S. E. Glova | ||
| "... emингибитора/em ангиотензинпревращающего фермента (иАПФ) эналаприла (Энам, Dr.Reddy’s). Материал и методы ..." | ||
| Vol 14, No 6 (2018) | Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer – New Scientific Evidences or Another Example of “Pseudo-Evidence” Medicine? | Abstract PDF (Eng) similar documents |
| S. Yu. Martsevich | ||
| "... eminhibitors/em contribute to the development of lung cancer is analyzed. The author notes that the analysis ..." | ||
| Vol 14, No 6 (2018) | The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial | Abstract PDF (Eng) similar documents |
| Yu. A. Karpov | ||
| "... to the achievement of target levels of atherogenic lipoproteins. PCSK9 eminhibitors/em, administered in addition ..." | ||
| Vol 2, No 4 (2006) | POSTMENOPAUSAL METABOLIC SYNDROME: CORRECTION OF AUTONOMIC NERVOUS SYSTEM DISBALANCE WITH COMBINATION OF ACE-INHIBITOR AND STATIN | Abstract similar documents |
| I. V. Logacheva, E. N. Shustova, E. V. Kulinich | ||
| "... (ACE eminhibitor/em and statin), not only have antihypertensive and hypolipidemic action, but also reduce ..." | ||
| Vol 2, No 4 (2006) | ANGIOTENSIN CONVERTING ENZYME INHIBITORS: DECREASE IN HEART REMODELING AND IMPROVEMENT IN FUNCTION OF ENDOTHELIUM IN PATIENTS WITH ARTERIAL HYPERTENSION | Abstract similar documents |
| K. Yu. Nikolaev, G. I. Lifshits, A. A. Nikolaeva, I. M. Gicheva | ||
| "... Aim. To estimate an effect of enalapril, angiotensin converting enzyme (ACE) eminhibitor/em , on left ..." | ||
| Vol 4, No 2 (2008) | INHIBITOR OF SYNTHESIS OF TUMOR NECROSIS FACTOR-Α, PENTOXIFYLLINE, IN COMBINED THERAPY OF THE CHRONIC HEART FAILURE | Abstract similar documents |
| O. P. Dudarenko, E. L. Shkol’nik, , , | ||
| Vol 20, No 2 (2024) | Metabolic reprogramming as the basis for sodium-glucose co-transporter type 2 inhibitors cardio- and nephroprotective effect | Abstract similar documents |
| O N. Kurochkina, D. A. Korotkov, A. S. Sazhina, A N. Bogomolov | ||
| "... In recent years, it has been shown that sodium-g lucose co-transporter type 2 eminhibitors/em (SGLT2 ..." | ||
| Vol 7, No 1 (2011) | SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW | Abstract similar documents |
| S. R. Gilyarevskiy, V. A. Orlov, M. V. Golshmid, G. Yu. Zakharova, I. I. Sinitsina | ||
| "... A role of angiotensin-converting enzyme (ACE) eminhibitors/em in cardiovascular diseases treatment ..." | ||
| 1 - 100 of 349 Items | 1 2 3 4 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
